ClinicalTrials.gg
CompletedNCT02800642CENTERAUpdated Jul 8, 2020Results posted

Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO

A Phase 4 interventional study of Aflibercept (Eylea, BAY86-5321) in Central Retinal Vein Occlusion, sponsored by Bayer. Completed at 42 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-08.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
162
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing aflibercept in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. aflibercept · Retinal Vein Occlusion.

Enrollment
6th of 21
162 · median 56
Started
2016
the only one that year
Phase 4
10 of 21
none open now
Registered
13th of 21
by date
Lead sponsor
2 of 21
Bayer

Among the 21 studies testing aflibercept in Retinal Vein Occlusion, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 10 in phase 4, and was the 13th registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

None of the 21 studies testing aflibercept in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing aflibercept in Retinal Vein Occlusion as a file.
02

Study summary

Central retinal vein occlusion (CRVO) occurs when the main blood vessel that transports blood away from the retina (the very back portion of the eye) becomes blocked, causing the leakage of fluid into the retina and thereby causing a swelling of the macula (the portion of the retina responsible for fine vision). This swelling is called macular edema. When the macula swells with fluid, central vision becomes blurry. The study drug aflibercept has been shown to reduce the amount of fluid and blood leaked into the retina. It can help to stabilize, and in many cases, improve the vision loss related to CRVO. Aflibercept has been approved for the treatment of macular edema secondary to CRVO in the United States (US), European Union (EU), Japan, and other countries.

The study was considered research because, although the study drug was already on the market for macular edema secondary to CRVO, there were no studies available that addressed the questions of what were useful intervals for treating and assessing patients, how did they differ among patients, and how were criteria applied for retreatment. The purpose of this study was to evaluate the effectiveness, treatment interval, and safety of the treatment regimen (pattern for administering treatment) in subjects with macular edema secondary to CRVO. In addition, this study explored new imaging methods for assessing the affected eye.

03

Conditions studied

  • Central Retinal Vein Occlusion

Keywords

  • Bayer
  • Aflibercept
  • Eylea
  • Intravitreal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Center-involved macular edema secondary to CRVO for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit).
  • Adult subjects diagnosed with macular edema secondary to CRVO who are scheduled to be treated with IVT aflibercept as per investigator's routine treatment practice with the intent to use a T\&E regimen after initial dosing.
  • Treatment-naïve subjects for macular edema secondary to CRVO.
  • Men and women ≥ 18 years of age.
  • Documented BCVA of ETDRS letter score of 73 to 24 letters (Snellen equivalent of 20/40 to 20/320) in the study eye.

Exclusion criteria

Exclusion Criteria:

  • Previous PRP or macular laser photocoagulation in the study eye.
  • Any prior or concomitant ocular treatment (e.g. anti-VEGF therapy, ) in the study eye for macular edema secondary to RVO, except dietary supplements or vitamins prior to inclusion in the study. Intraocular anti-VEGF treatment is permitted for the treatment of diseases of fellow eye except for those that are specifically excluded.
  • Prior systemic anti-VEGF or corticosteroid therapy, or approved, within the last 3 months before the first dose in the study.
  • Previous use of intraocular corticosteroids in the study eye at any time or use of periocular corticosteroids in the study eye within 12 months prior to Day 1.
  • Any active intraocular, extraocular, and periocular inflammation or infection in either eye within 4 weeks of screening.
  • Any history of allergy to povidone iodine.
  • Known serious allergy to the fluorescein sodium for injection in angiography.
  • Presence of any indicated in the EU commission/locally approved label for IVT aflibercept: to the active substance IVT aflibercept or to any of the ; active or suspected ocular or periocular infection; active severe intraocular inflammation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Intravitreal (IVT) aflibercept

    Participants with macular edema secondary to CRVO were treated with the study drug intravitreal aflibercept

    Drug: Aflibercept (Eylea, BAY86-5321)

Interventions

  • The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.

06

What researchers measure

Primary outcomes

  1. The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline

    Participants who completed the study with a gain of ≥ 15 letters or dropped the study after Week 24 and having a permanent resolution of macular edema and a gain of ≥ 15 letters from baseline with regard to the latest BCVA assessment. The ETDRS chart includes 70 letters in total, more letters read correctly represents a better visual acuity.

    Time frame: Baseline, Week 24 and Week 76

  2. The Proportion of Participants With a Mean Treatment Interval Between Injections of ≥ 8 Weeks

    Participants who completed the study with a mean treatment interval between injections of ≥ 8 weeks or dropped out of the study after Week 24 and having a permanent resolution of macular edema

    Time frame: From the last actual visit of the initiation phase to Week 76

Secondary outcomes

  1. The Mean Treatment Interval Between Injections

    Time frame: From baseline to Week 76

  2. The Change in Best Corrected Visual Acuity (BCVA) as Measured by the Early Treatment Diabetic Retinopathy Letter Score (ETDRS) From Baseline

    The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity

    Time frame: Baseline and Week 24, 52, and 76

  3. The Change in Central Retinal Thickness (CRT) From Baseline

    CRT was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).

    Time frame: Baseline and Week 24, 52 and 76

  4. The Number of Injections Per Participant

    Time frame: From baseline to Week 76

  5. The Proportion of Participants Who Gain ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline

    The ETDRS chart includes 70 letters in total. More letters read correctly represents a better visual acuity

    Time frame: Baseline and Week 24, Week 52

  6. The Proportion of Participants With Change in Retinal Non-perfusion (FA/FP) Status From Baseline

    The change in retinal non-perfusion status by fundus angiography (FA)/fundus photography (FP)-confirmed ischemic disc area. The status was categorized into: no non-perfusion, \<10 ischemic disc area, \>=10 ischemic disc area and missing status

    Time frame: Baseline and Week 24, 52 and 76

  7. The Proportion of Participants With Absence of Subretinal Fluid

    Time frame: Baseline, week 24, week 52 and week 76

  8. Incidence and Severity of Ocular Treatment-emergent Adverse Events

    Time frame: Up to 30 days after week 76

07

Results

Posted Jul 8, 2020

Participant flow

A total of 244 participants were screened in 42 study centers in 8 countries, the first subject first visit was on 10/Jun/2016 and last subject last visit was on 31/Jun/2019

Participant flow — Overall Study
MilestoneIntravitreal (IVT) Aflibercept
Started162
Completed137
Not completed25
Withdrew: Death3
Withdrew: Other10
Withdrew: Physician decision2
Withdrew: Adverse event6
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up1

Outcome measures

SecondaryThe Mean Treatment Interval Between Injections
Time frame:
From baseline to Week 76
Reported as:
Mean · weeks
The Mean Treatment Interval Between Injections
weeksIntravitreal (IVT) Aflibercept
The Mean Treatment Interval Between Injections6.37 ± 1.150
PrimaryThe Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline

Participants who completed the study with a gain of ≥ 15 letters or dropped the study after Week 24 and having a permanent resolution of macular edema and a gain of ≥ 15 letters from baseline with regard to the latest BCVA assessment. The ETDRS chart includes 70 letters in total, more letters read correctly represents a better visual acuity.

Time frame:
Baseline, Week 24 and Week 76
Reported as:
Number · percent
The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline
percentIntravitreal (IVT) Aflibercept
The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline65.6 ± 57.7
Statistical analysis
  • Intravitreal (IVT) Aflibercept · Exact one-sided 1-sample binomial test · p = <0.0001
PrimaryThe Proportion of Participants With a Mean Treatment Interval Between Injections of ≥ 8 Weeks

Participants who completed the study with a mean treatment interval between injections of ≥ 8 weeks or dropped out of the study after Week 24 and having a permanent resolution of macular edema

Time frame:
From the last actual visit of the initiation phase to Week 76
Reported as:
Number · percent
The Proportion of Participants With a Mean Treatment Interval Between Injections of ≥ 8 Weeks
percentIntravitreal (IVT) Aflibercept
The Proportion of Participants With a Mean Treatment Interval Between Injections of ≥ 8 Weeks45.0 ± 37.1
Statistical analysis
  • Intravitreal (IVT) Aflibercept · Exact one-sided 1-sample binomial test · p = =0.8822
SecondaryThe Change in Best Corrected Visual Acuity (BCVA) as Measured by the Early Treatment Diabetic Retinopathy Letter Score (ETDRS) From Baseline

The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity

Time frame:
Baseline and Week 24, 52, and 76
Reported as:
Mean · scores
The Change in Best Corrected Visual Acuity (BCVA) as Measured by the Early Treatment Diabetic Retinopathy Letter Score (ETDRS) From Baseline
scoresIntravitreal (IVT) Aflibercept
Absolute BCVA letter score at baseline51.9 ± 16.8
Absolute BCVA letter score at Week 2472.4 ± 16.6
Absolute BCVA letter score at Week 5271.8 ± 18.1
Absolute BCVA letter score at Week 7672.3 ± 18.5
Change from baseline at Week 2420.4 ± 17.0
Change from baseline at Week 5219.9 ± 19.1
Change from baseline at Week 7620.3 ± 19.5
SecondaryThe Change in Central Retinal Thickness (CRT) From Baseline

CRT was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).

Time frame:
Baseline and Week 24, 52 and 76
Reported as:
Mean · micrometer
The Change in Central Retinal Thickness (CRT) From Baseline
micrometerIntravitreal (IVT) Aflibercept
Absolute CRT at baseline759.9 ± 246.0
Absolute CRT at Week 24271.2 ± 53.1
Absolute CRT at Week 52279.8 ± 106.8
Absolute CRT at Week 76265.4 ± 57.9
Change from baseline at Week 24-488.9 ± 254.6
Change from baseline at Week 52-481.3 ± 266.5
Change from baseline at Week 76-496.1 ± 252.4
SecondaryThe Number of Injections Per Participant
Time frame:
From baseline to Week 76
Reported as:
Mean · injections
The Number of Injections Per Participant
injectionsIntravitreal (IVT) Aflibercept
The Number of Injections Per Participant12.2 ± 2.53
SecondaryThe Proportion of Participants Who Gain ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline

The ETDRS chart includes 70 letters in total. More letters read correctly represents a better visual acuity

Time frame:
Baseline and Week 24, Week 52
Reported as:
Number · percent
The Proportion of Participants Who Gain ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to Baseline
percentIntravitreal (IVT) Aflibercept
Week 2468.8 ± 61.0
Week 5268.1 ± 60.3
SecondaryThe Proportion of Participants With Change in Retinal Non-perfusion (FA/FP) Status From Baseline

The change in retinal non-perfusion status by fundus angiography (FA)/fundus photography (FP)-confirmed ischemic disc area. The status was categorized into: no non-perfusion, \<10 ischemic disc area, \>=10 ischemic disc area and missing status

Time frame:
Baseline and Week 24, 52 and 76
Reported as:
Number · percent
The Proportion of Participants With Change in Retinal Non-perfusion (FA/FP) Status From Baseline
percentIntravitreal (IVT) Aflibercept
Baseline to week 24: no to <104.4
Baseline to week 24: no to >=103.8
Baseline to week 24: no to missing6.3
Baseline to week 24: <10 to no0.6
Baseline to week 24: <10 to >=100.6
Baseline to week 24: <10 to missing0
Baseline to week 24: >=10 to no1.3
Baseline to week 24: >=10 to <100
Baseline to week 24: >=10 to missing0.6
Baseline to week 24: missing to no0
Baseline to week 24: missing to <100.6
Baseline to week 24: missing to >=100.6
Baseline to week 24: no status change81.9
Baseline to week 52: no to <105.0
Baseline to week 52: no to >=105.6
Baseline to week 52: no to missing10.6
Baseline to week 52: <10 to no1.9
Baseline to week 52: <10 to >=100
Baseline to week 52: <10 to missing0
Baseline to week 52: >=10 to no1.9
Baseline to week 52: >=10 to <100
Baseline to week 52: >=10 to missing0
Baseline to week 52: missing to no0
Baseline to week 52: missing to <100.6
Baseline to week 52: missing to >=100.6
Baseline to week 52: no status change73.8
Baseline to week 76: no to <103.1
Baseline to week 76: no to >=104.4
Baseline to week 76: no to missing18.1
Baseline to week 76: <10 to no1.3
Baseline to week 76: <10 to >=100.6
Baseline to week 76: <10 to missing0.6
Baseline to week 76: >=10 to no0.3
Baseline to week 76: >=10 to <100
Baseline to week 76: missing to no0
Baseline to week 76: missing to <100.6
Baseline to week 76: missing to >=100.6
Baseline to week 76: no status change69.4
SecondaryThe Proportion of Participants With Absence of Subretinal Fluid
Time frame:
Baseline, week 24, week 52 and week 76
Reported as:
Number · percent
The Proportion of Participants With Absence of Subretinal Fluid
percentIntravitreal (IVT) Aflibercept
Baseline25.6 (19.1 to 33.1)
Week 2498.7 (95.4 to 99.8)
Week 5295.4 (90.8 to 98.1)
Week 7697.8 (93.7 to 99.5)
SecondaryIncidence and Severity of Ocular Treatment-emergent Adverse Events
Time frame:
Up to 30 days after week 76
Reported as:
Count of participants · Participants
Incidence and Severity of Ocular Treatment-emergent Adverse Events
ParticipantsIntravitreal (IVT) Aflibercept
Any ocular TEAEs90
Severity: mild39
Severity: moderate43
Severity: severe8

Adverse events

Collected over Up to 30 days after week 76. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravitreal (IVT) Aflibercept4/162 (2.5%)32/162 (19.8%)81/162 (50%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventIntravitreal (IVT) Aflibercept
Atrial fibrillationCardiac disorders4/162
Retinal ischaemiaEye disorders2/162
Gastric ulcerGastrointestinal disorders2/162
ThrombocytopeniaBlood and lymphatic system disorders1/162
Atrial flutterCardiac disorders1/162
Bundle branch block bilateralCardiac disorders1/162
Cardiac failure acuteCardiac disorders1/162
Mitral valve incompetenceCardiac disorders1/162
Ventricular tachycardiaCardiac disorders1/162
Amaurosis fugaxEye disorders1/162
Most frequent other events
Most frequent other events
EventIntravitreal (IVT) Aflibercept
Visual acuity reducedEye disorders26/162
NasopharyngitisInfections and infestations26/162
Intraocular pressure increasedInvestigations20/162
HypertensionVascular disorders19/162
Conjunctival haemorrhageEye disorders18/162
Retinal haemorrhageEye disorders14/162
Retinal ischaemiaEye disorders13/162
Macular oedemaEye disorders12/162
Vitreous detachmentEye disorders9/162
Foreign body sensation in eyesEye disorders9/162

Baseline characteristics

Safety analysis set: all participants who received any study drug

Age, Continuous
Age, Continuous(years)Intravitreal (IVT) Aflibercept
Mean66.4 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Intravitreal (IVT) Aflibercept
Female65
Male97
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intravitreal (IVT) Aflibercept
Hispanic or Latino2
Not Hispanic or Latino156
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intravitreal (IVT) Aflibercept
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White154
More than one race0
Unknown or Not Reported4
08

Study locations

42 sites
  • Albury, New South Wales 2640, Australia
  • Sydney, New South Wales 2000, Australia
  • Parramatta, 2150, Australia
  • Calgary, Alberta T2H 0C8, Canada
  • Hamilton, Ontario L8G 5E4, Canada
  • London, Ontario N6A 4V2, Canada
  • Boisbriand, Quebec J7H 1S6, Canada
  • Sherbrooke, Quebec J1G 2V4, Canada
  • Quebec, G1V 1T6, Canada
  • Aalborg, 9100, Denmark
  • Glostrup, 2600, Denmark
  • Bordeaux, 33076, France
  • Dijon Cedex, BP 1542-21, France
  • Lyon, 69004, France
  • Freiburg, Baden-Württemberg 79106, Germany
  • Heidelberg, Baden-Württemberg 69120, Germany
  • Karlsruhe, Baden-Württemberg 76133, Germany
  • Augsburg, Bayern 86156, Germany
  • Göttingen, Niedersachsen 37075, Germany
  • Düsseldorf, Nordrhein-Westfalen 40225, Germany
  • Hannover, Nordrhein-Westfalen 30625, Germany
  • Köln, Nordrhein-Westfalen 50935, Germany
  • Münster, Nordrhein-Westfalen 48149, Germany
  • Leipzig, Sachsen 04103, Germany
  • Roma, Lazio 00133, Italy
  • Roma, Lazio 00198, Italy
  • Milano, Lombardia 20132, Italy
  • Milano, Lombardia 20157, Italy
  • Ancona, Marche 60126, Italy
  • Pisa, Toscana 56124, Italy
  • Padova, Veneto 35128, Italy
  • Oviedo, Asturias 33012, Spain
  • Sant Cugat del Vallés, Barcelona 08195, Spain
  • Viladecans, Barcelona 08840, Spain
  • Barcelona, 08024, Spain
  • Barcelona, 08025, Spain
  • Sunderland, Tyne And Wear SR2 9HP, United Kingdom
  • Bradford, West Yorkshire BD9 6RJ, United Kingdom
  • Bristol, BS1 2LX, United Kingdom
  • Colchester, CO3 3NB, United Kingdom
  • Liverpool, L9 7AL, United Kingdom
  • Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Korobelnik JF, Larsen M, Eter N, Bailey C, Wolf S, Schmelter T, Allmeier H, Chaudhary V. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study. Am J Ophthalmol. 2021 Jul;227:106-115. doi: 10.1016/j.ajo.2021.01.027. Epub 2021 Feb 6. PubMed 33556381 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Jul 2019, 37 months.

Results were first posted in Jul 2020, 11 months after primary completion.

Of 19 phase 4 interventional studies under Retinal Vein Occlusion, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2016
First posted
Jun 15, 2016
StartActual
Jun 10, 2016
Primary completionActual
Jul 31, 2019
CompletionActual
Jul 31, 2019
Results first posted
Jul 8, 2020
Last update
Jul 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02800642
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 15, 2016
Start date
Jun 10, 2016
Primary completion
Jul 31, 2019
Completion
Jul 31, 2019
Results posted
Jul 8, 2020
Last update
Jul 8, 2020

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion